Singapore, Aug. 27 -- Brightonix Imaging, a South Korea-based startup, has announced that its flagship product, the PHAROS PET Scanner, has received USFDA clearance for commercial distribution in the United States (US).

This milestone marks a new era of precision and efficiency in nuclear imaging and positions Brightonix Imaging at the forefront of medical innovation.

The PHAROSPET is a state-of-the art clinical positron emission tomography (PET) system designed to deliver exceptional image quality, offering healthcare providers a powerful tool for early disease detection, precise diagnosis, and optimized treatment planning.

With its innovativedesign and enhanced performance capabilities, the PHAROS scanner is poised to set new standar...